Gallbladder Treatment

Resectable

ECOG-ACRIN-EA2197
Phase II/III
Optimal
Perioperative
Therapy for
Incidental
Gallbladder
Cancer (OPT-IN)
PI: Poultsides
Sponsor: ECOG-ACRIN

GI0027
Brightline-2:
Phase IIa/IIb
907828 in Locally
Advanced / Metastatic, MDM2
Amplified TPS3
Wild-Type Biliary
Tract
Adenocarcinoma
Pancreatic Ductal
Adenocarcinoma
or Other Selected
Solid Tumours
PI: Chen
Sponsor: Boehringer
Ingelheim Pharmaceuticals, Inc.

Unresectable Metastatic

GI0026
Phase II/III
Randomized
Controlled Study
of CTX-009 in
Combo w/
Paclitaxel vs
Paclitaxel Alone in
Adult
Unresectable
Advanced
Metastatic or
Recurrent Biliary
Tract Cancers
Who Have
Received One
Prior Systemic
Chemotherapy
Regimen
PI: Heestand
Sponsor: Compass
Therapeutics, Inc.

2nd Line

KEY

Pending
Open for Enrollment
Observational Study
− − Optional Path
Link
Trial Posting
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu